Thomas Dietz

Dr. Dietz has more than 25 years of experience supporting the biotechnology and biopharmaceutical industries and the institutional investment community. Prior to his current role as Chairman and CEO of Waypoint Holdings, Dr. Dietz was co-CEO and then CEO and a Director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities. Dr. Dietz served as head of the investment banking division at Wedbush until November 2010. Prior to becoming CEO at Pacific Growth, Dr. Dietz served as the firm’s Director of Equities Research and was an award-winning biotechnology and biopharmaceutical analyst. Dr. Dietz joined Pacific Growth in 1993. Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Additionally, Dr. Dietz serves as Chairman of Galleon Pharmaceuticals, Inc., and Virobay, Inc. Dr. Dietz is also a Director of Paratek Pharmaceuticals (NASDAQ: PRTK), Glialogix, Inc., Rogne Biosciences, and Sutter Health System’s West Bay Region. Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow.